NCT04236297 is a NA clinical trial of bite block in Bite Block, sponsored by University of Washington.

Who is sponsoring NCT04236297?

NCT04236297 is sponsored by University of Washington.

What drugs are being tested in NCT04236297?

Interventions in NCT04236297: bite block.

What condition does NCT04236297 study?

NCT04236297 studies Bite Block.

Is NCT04236297 still recruiting?

NCT04236297 is currently completed. Last updated 15 April 2022.

Last reviewed 2022-04-15 · How we verify

NCT04236297

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Modified Bite-Block for Invasive Imaging Procedures

Completed NA Last updated 15 April 2022

What this trial tests

NA trial testing bite block in Bite Block in 50 participants. Completed in 31 December 2020.

Timeline

22 August 2019

Primary endpoint
30 August 2020

31 December 2020

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	22 August 2019
Primary completion	30 August 2020
Estimated completion	31 December 2020
Sites	1 location across United States

Drugs / interventions tested

bite block

Conditions studied

Bite Block — all drugs for Bite Block →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Bite Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare a modified bite block with standard bite block during transesophageal echocardiography procedures in patients who are either sedated or under general anesthesia. These dental protector devices are class I devices which are exempt from the FDA 510(k) premarket notification requirements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04236297 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 15 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04236297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing